At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLDX Celldex Therapeutics
Market Closed 07-10 16:00:00 EDT
39.11
+0.13
+0.33%
盘后39.11
+0.000.00%
16:52 EDT
High39.19Low37.81Vol694.01K
Open38.90D1 Closing38.98Amplitude3.54%
Mkt Cap3.07BTradable Cap2.83BTotal Shares78.49M
T/O26.90MT/O Rate0.96%Tradable Shares72.46M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed?
Simply Wall St.  ·  07-06
Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed?
Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus
Simply Wall St.  ·  07-02
Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus
Celldex Therapeutics Shareholders Approve 3,400,000-share Increase to 2021 Equity Plan at Annual Meeting
Reuters  ·  06-26
Celldex Therapeutics Shareholders Approve 3,400,000-share Increase to 2021 Equity Plan at Annual Meeting
Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data
Simply Wall St.  ·  06-20
Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
InvestorPlace  ·  06-19
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
Why Celldex Therapeutics (CLDX) Is Up 12.2% After CSU Drug Data Suggest Disease Modification Potential
Simply Wall St.  ·  06-18
Why Celldex Therapeutics (CLDX) Is Up 12.2% After CSU Drug Data Suggest Disease Modification Potential
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  06-15
Wall Street Analysts Are Bullish on Top Healthcare Picks
Celldex Therapeutics Price Target Maintained With a $42.00/Share by HC Wainwright & Co.
Dow Jones  ·  06-15
Celldex Therapeutics Price Target Maintained With a $42.00/Share by HC Wainwright & Co.
Celldex presents long-term results from Phase 2 study of barzolvolimab
TIPRANKS  ·  06-15
Celldex presents long-term results from Phase 2 study of barzolvolimab
Celldex presents first-in-human results for CDX-622
TIPRANKS  ·  06-15
Celldex presents first-in-human results for CDX-622
Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study
Reuters  ·  06-14
Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study
Celldex says Phase 2 barzolvolimab data show sustained off-treatment angioedema improvement in CSU patients
Reuters  ·  06-14
Celldex says Phase 2 barzolvolimab data show sustained off-treatment angioedema improvement in CSU patients
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained off-Treatment Improvement in Angioedema in Patients With Csu at the European Academy of Allergy and Clinical Immunology Annual Meeting
THOMSON REUTERS  ·  06-14
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained off-Treatment Improvement in Angioedema in Patients With Csu at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex Therapeutics - Barzolvolimab Meets Primary Efficacy Endpoint in Phase 2 Csu Study
THOMSON REUTERS  ·  06-14
Celldex Therapeutics - Barzolvolimab Meets Primary Efficacy Endpoint in Phase 2 Csu Study
Celldex reports positive Phase 1 results for bispecific antibody CDX-622 in healthy participants
Reuters  ·  06-14
Celldex reports positive Phase 1 results for bispecific antibody CDX-622 in healthy participants
Celldex Presents Positive First-in-Human Results From Phase 1 Study of Novel Bispecific Cdx-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
THOMSON REUTERS  ·  06-14
Celldex Presents Positive First-in-Human Results From Phase 1 Study of Novel Bispecific Cdx-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex to present barzolvolimab, CDX-622 data at EAACI annual congress
Reuters  ·  06-11
Celldex to present barzolvolimab, CDX-622 data at EAACI annual congress
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
GlobeNewswire  ·  06-11
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
Celldex Therapeutics Is Maintained at Buy by UBS
Dow Jones  ·  06-11
Celldex Therapeutics Is Maintained at Buy by UBS
UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating
MT Newswires Live  ·  06-10
UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating

Introduction

Company Name.
Celldex Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Issue price:
--